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TCDD is an environmental toxin that has been well characterized to attenuate
experimental autoimmune encephalomyelitis (EAE), a mouse model used to study multiple
sclerosis. To evaluate the effect of TCDD on B cells in various anatomic locations in EAE, the
expression of B cell markers, including CD19, B220, and CD5; the expression of IgG; and the
expression of CD24 and CD38, which together signify a regulatory B cell, were evaluated in
each location. In mice with EAE, TCDD increased CD19 and B220 expression and suppressed
IgG expression in the spleen and increased the CD5+CD24+CD38+ population in the spinal
cord, suggesting that TCDD’s target organs at end-stage disease are spleen and spinal cord.
These findings provide insight into the mechanism of immunotoxicity of TCDD and contribute
to the understanding of how AhR ligands affect EAE, which could lead to development of a less
toxic AhR compound for treatment of autoimmune disease.
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CHAPTER I
INTRODUCTION
Immunotoxicology. This seemingly big word, when broken down, essentially means the
study of toxic substances and their effects on the immune system. Toxic substances are prevalent
throughout the world and in a variety of settings, and the immune system is crucial for human
survival. Often, toxins target the immune system in order to exert their harmful effects on the
human body (Dean, 1994). Therefore, studying the ways in which immunology and toxicology
overlap is crucial to not only preventing harmful health effects from toxins but also developing
less toxic treatments for certain diseases. The studies described in the following pages fall into
the category of immunotoxicology because they seek to evaluate the effects of a ubiquitous
environmental toxin, 2,3,7,8-terachlorodibenzo-p-dioxin (TCDD) on the immune system using
the mouse model of multiple sclerosis (MS), an autoimmune disease.
Although it is well-known for being a contaminant in the herbicide Agent Orange, TCDD
is also an unintentional byproduct of many chemical and industrial processes, including the
combustion of fossil fuels, the burning of waste, the production of pulp and paper, and the
manufacture of some organic chemicals. Low levels of TCDD may be found in the air, soil, and
food, including meat, fish, and dairy products. Therefore, it is likely that all humans have been
exposed to TCDD at some point in their life. Because TCDD is the most toxic of all known
dioxins, a specific group of environmental pollutants, studying its effects on human health is
very important. These effects are vast and diverse; TCDD has been linked to cardiovascular
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disease, liver abnormalities, skin deformities, and cancer. However, for the purpose of this paper,
it is important to note that TCDD has been well characterized to be immunosuppressive (White
and Birnbaum, 2009).
TCDD is also a prototypical aryl hydrocarbon receptor (AhR) ligand. AhR is a
transcription factor located in the cytosol. When activated by the binding of a ligand, AhR moves
to the nucleus where it regulates the expression of many genes. Studies have shown that
activated AhR can integrate signals from the environment and other cell processes to modulate
the immune response (Wheeler et al., 2017). Because TCDD is an AhR ligand, it is thought that
TCDD exerts its immunosuppressive effects by binding and activating AhR, leading to a cascade
of immune processes that reduce inflammation (Neavin et al., 2018).
The suppression of the immune system can be deleterious and lessen a person’s ability to
fight disease, but suppression may also be beneficial, specifically in the presence of autoimmune
disease. One such disease is MS, an autoimmune-mediated disorder of the central nervous
system. Although the exact cause of MS can vary, the disorder leads to the death of neurons and
demyelination of nerves. This destruction of nerve tissue results in an inflammatory response in
which lesions form in the CNS. These lesions then interfere with normal neuronal functions and
can result in visual disturbances, fatigue, loss of muscle control and coordination, and paralysis,
as well as emotional difficulties and thinking problems (Ghasemi et al., 2017).
To study MS, an animal model called experimental autoimmune encephalomyelitis
(EAE) may be used (Constantinescu et al., 2011). In previous studies using the EAE model,
TCDD has been shown to slow the onset of disease and lessen disease severity. Although TCDD
attenuates EAE, it is still important to understand how it is exerting its immunosuppressive
effects. Our previous studies have mainly examined TCDD’s effect on T cell function, a
2

component of the specific immune response, in the spleens of diseased mice (Yang et al., 2016).
The purpose of these studies was to assess TCDD’s effect on B cells, which make up the
humoral immune response. Comparing the effect of TCDD on specific B cell subsets within
different anatomic locations, including the spleen, bone marrow, lymph nodes, and spinal cord
provides a more holistic look at the ways in which TCDD attenuates EAE disease via
immunosuppressive mechanisms in the nervous system.
Through these studies, we aimed to gain novel information about TCDD’s effect in
multiple tissues at end-stage disease. The effects on the spleen and spinal cord have been studied
more in depth, so we sought to understand if TCDD was also having an effect in the bone
marrow and lymph nodes. To evaluate the effects on the different tissues, we analyzed the
expression of multiple B cell markers, including two that have not been studied extensively.
Additionally, we evaluated the production of IgG, an antibody crucial to mounting an immune
response, and the expression of a B cell regulatory population at end stage disease. Lastly, by
conducting independent studies with both male and female mice, we sought to determine if
TCDD had any sex-specific immunosuppressive mechanisms.
Overall, these studies aid in understanding the toxicity of TCDD and identifying its
mechanism of immune suppression. These findings can then be used to help prevent the
deleterious effects of environmental toxins and to potentially identify less toxic, AhR-binding
compounds as treatments for autoimmune disease. Altogether, results from immunotoxicology
studies like this one help to make progress in the realm of public and individual human health.
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CHAPTER II
BACKGROUND
As mentioned above, EAE is an animal model that closely mimics MS in humans. EAE is
similar to MS in that it leads to inflammation and demyelination. However, EAE is different in
that it must be induced via active immunization with an emulsion of complete Freud’s adjuvant
(CFA) and myelin oligodendrocyte glycoprotein (MOG). CFA contains heat-killed
Mycobacterium tuberculosis, which activates the innate immune response, and MOG is a
component of the myelin sheath surrounding neurons. Together, CFA and MOG induce an
inflammatory CNS immune response similar to that of MS (Constantinescu et al., 2011).
TCDD has previously been shown to attenuate disease and affect the immune response in
the EAE model by suppressing T cell effector function and increasing CD4+CD25+FOXP3+ T
regulatory cells (Yang et al., 2016). Our preliminary results also show that TCDD inhibited IgG
production in EAE; TCDD suppressed MOG-specific IgG, as well as intracellular IgG
production in the spleen and spinal cord in CD19- cells (Kummari et al.). The inhibition of IgG
production by TCDD demonstrates that the AhR ligand affects B cells. To further evaluate
TCDD’s effect, we analyzed IgG expression in other B cells, specifically CD19, B220, and CD5
negative populations, in the spleen, lymph nodes, and bone marrow. CD19, a transmembrane
glycoprotein, and B220, a CD45 isoform specific to murine B cells, are B cell markers
expressed in all stages of B cell development but lost upon plasma cell differentiation (Wang et
al., 2012, Cascalho et al., 2000). CD5 is a surface glycoprotein expressed in one subset of innate
4

B cells, known as B1a. Its expression is highest in B cells with regulatory functions (Fenutría et
al., 2014).
Since our previous studies showed that TCDD suppressed EAE by inhibiting T effector
function and inducing T regulatory function (Yang et al., 2016), we sought to determine if
TCDD would affect a regulatory B cell population. Regulatory B cells help modulate the
immune response by either suppressing other immune cells or inducing regulatory cells (Mauri
and Menon, 2017). Our preliminary results showed that TCDD modestly upregulated FasL
expression in CD19+ B cells in EAE, and FasL is just one cell surface marker on B cells that
defines the B cells as regulatory (Kummari et al.). Therefore the focus of these studies was to
determine if TCDD would affect another regulatory B cell population, one defined by coexpression of CD24 and CD38 (Mauri and Menon, 2017), which play a role in controlling T
effector function and inducing T regulatory function. We hypothesized that TCDD would
suppress IgG and induce CD24 and CD38 in B cells isolated from the spleens, lymph nodes,
bone marrow, and spinal cords of male and female mice with EAE.
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CHAPTER III
MATERIALS AND METHODS
Mice
Male and female C57BL/6 wild type (WT) mice were obtained from Envigo
(Indianapolis, IN) at 6-8 weeks of age. The mice were kept 3 to a cage in a sterile, temperature
(22 +/- C) and light controlled (12-h light: 12-h dark) room. Each experimental group contained
3 mice. Food and water were provided ad libitum. Mississippi State University Institutional
Animal Care and Use Committee approved the experimental protocols.
EAE Induction and Clinical Evaluation
Mice were immunized with 100 g of myelin oligodendrocyte glycoprotein (MOG)
peptide (Anaspec, Fremont, CA; MEVGWYRSPFSRVVHLYRNGK) in Complete Freund’s
Adjuvant (CFA) supplemented to 5 μg/ml heat-killed Mycobacterium tuberculosis H37Ra
(Difco, Detroit, MI). Mice were anesthetized with isoflurane and injected with the MOG/CFA
emulsion in four flanks (25 μl each; 2 at the hips, 2 at the shoulders) subcutaneously. EAE was
induced in mice on day 0 and TCDD or CO was administered by oral gavage on days 1-12.
Mice were weighed every other day until day 10 then daily thereafter. Mice were assigned
clinical scores based on the following scoring system: 0, healthy; 0.5, flaccid tail; 1, awkward
gait; 2; able to be flipped over; 3, single hind limb paralysis; 4, dual hind limb paralysis. Mice
were not permitted to progress beyond a clinical score of 4.
6

TCDD Administration
TCDD (Accustandard, New Haven, CT) was dissolved in corn oil (CO) to make a stock
solution. Prior to administration, the stock solution was further diluted in CO. Mice were given
2.5 g/kg/day of TCDD or CO via oral gavage each day for twelve days, starting the day after
disease induction. Dosage was chosen based on previous experiments in which 2.5 g/kg/day of
TCDD attenuated EAE. Using this dosing paradigm allowed for the evaluation of subchronic,
low dose TCDD exposure prior to the development of clinical signs of disease in the mice.
Splenocyte, Lymph Node, Bone Marrow, and Spinal Cord Cell Isolation
Mice were necropsied on day 18. The spleen was harvested and placed in a plate and
mechanically disrupted in 1ml of serum-free 1 x Roswell Park Memorial Institute (RPMI) 1640
media (Gibco, Grand Island, New York). The crude single cell preparation was collected and
centrifuged at 400 x g for 5 minutes at RT. The SPLC pellet was resuspended in 1ml culture
media (RPMI with 5% bovine calf serum, 1% penicillin-streptomycin and 50 µM 2mercaptoethanol) and counted using an ACEA Novocyte flow cytometer. Lymph nodes (pooled
from axillary and inguinal lymph nodes) were collected and mechanically disrupted. Bone
marrow was isolated from the femur. The spinal column was harvested, and the spinal cord was
excised and placed in 1X phosphate-buffered saline (PBS). Spinal cords were cut into pieces and
digested with collagenase and DNase for 45 min at 37°C after which lymphocytes were
separated using a 30%-70% percoll gradient. Lymphocytes were isolated from the buffy coat in
the middle of the gradient after centrifugation.
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Cell Staining
Cells were stained on the day of necropsy. Isolated cells were resuspended in 1X PBS.
Cells were washed once with 1X PBS, centrifuged at 500 x g for 5 min at RT, and the
supernatant was discarded. Cells were incubated with Near-IR Fixable Viability Dye (FVD,
BioLegend, San Diego, California) for 30 min at room temperature (RT) to collect live cells via
negative fluorescence intensity of FVD. Cells were washed again with PBS and then with flow
cytometry (FCM) buffer. Then cells were treated with mouse Fc block for 15 minutes at RT.
Cells for IgG staining were also blocked with extracellular IgG. Next, cells were labeled with the
fluorescently conjugated antibodies for surface markers in the dark for 30 min at RT. The
antibodies used for staining of cell surface markers are as follows (all antibodies were purchased
from BioLegend): panel 1: APC IgG, PE-Cy7 CD19, BV785 B220, BV421 CD5; panel 2: PECy7 CD19, BV785 B220, BV421 CD5, PE CD24, APC CD38. The antibodies were delivered in
50 µl of FCM buffer. Cells were washed with FCM buffer and fixed using Cytofix (BD
Biosciences). Cells for IgG staining were permeabilized with Perm Wash Buffer (BD
Pharmingen, San Jose, California). IgG antibody was delivered in Perm Wash Buffer for
intracellular staining. All cells were analyzed using an ACEA Novocyte.
Flow Cytometry Analysis
Data analysis was performed using NovoExpress software. High fluorescent intensity of
FVD was used to exclude dead cells. Forward scatter vs. side scatter properties of the live cells
were used to gate the lymphocyte population, and the lymphocyte population was further gated
on side scatter area versus height to exclude doublets. Bead controls were prepared for
compensation, and fluorescence minus one cell controls were used to establish the gating for
each fluorochrome in the staining mixture.
8

Statistical Analysis
GraphPad Prism 7 was used to perform statistical analysis. Comparisons between the
experimental groups were calculated by two-way ANOVA tests. The level of significance was
defined as p < 0.05.
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CHAPTER IV
RESULTS
Clinical Evaluation
There were no significant changes in body weight (data not shown). EAE mice that
received CO started showing clinical signs around day 17. In the first experiment, disease at day
18 was still very mild in all mice. In experiments 2 and 3, most EAE/CO mice reached a clinical
score of 0.5-1.5 by day 18, meaning they exhibited loss of tail tone and had an awkward gait.
TCDD modestly attenuated clinical disease in all three experiments, and TCDD-treated EAE
mice had clinical scores very similar to mice without EAE (Figure 4.1).
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Figure 4.1
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TCDD modestly reduced clinical scores

EAE was induced in C57BL/6 mice on day 0 (n=3). Mice received or 2.5 µg/kg/day TCDD by
oral gavage on days 1-12. Clinical scores were assessed every other day for the first 10 days then
daily until necropsy on day 18. Examples of clinical scores are: 0.5, flaccid tail; 1, awkward gait;
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2, susceptible to flipping over without ability to right self; 3, single hind limb paralysis; 4, dual
hind limb paralysis.
CD19, B220, and CD5 Expression in Various Tissues
Overall, CD19 was most highly expressed in the spleens of both male and female mice.
TCDD modestly increased CD19 expression in the spleens of mice with and without EAE. In the
bone marrow and lymph nodes, CD19 expression was variable and was not consistently affected
by TCDD (Table 4.1).
In general, B220 was also most highly expressed in the spleen, and TCDD tended to
increase B220 expression in the spleens of male and female mice. TCDD slightly increased B220
in the bone marrow of male and female mice with disease. B220 expression in the lymph nodes
was the most variable. In the lymph nodes of females, TCDD increased B220 expression. In the
lymph nodes of males, B220 expression was lower than in females, and TCDD did not have a
consistent effect on B220 expression (Table 4.2).
CD5 was most highly expressed in the lymph nodes of both male and female mice. The
effect of TCDD on CD5 expression in the lymph nodes was variable in male and female mice
with and without disease. TCDD did not affect CD5 expression in the spleen and had
inconsistent effects on CD5 expression in the bone marrow (Table 4.3).
Interestingly, CD19 and B220 expression was correlated, especially in the bone marrow
and lymph nodes, regardless of disease or treatment (Figure 4.2).
Table 4.1

CD19 expression in splenocytes (SPLC), bone marrow (BM), and lymph nodes
(LN) in two independent experiments.
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%CD19
SAL/CO
SAL/TCDD
EAE/CO
EAE/TCDD

Female SPLC
41.89 +/- 7.91
54.87 +/- 10.76
30.24 +/- 1.86
44.73 +/- 3.00

Male SPLC
41.17 +/- 9.69
67.91 +/- 0.39
23.57 +/- 4.93
25.60 +/- 1.78

Female BM
32.79 +/- 2.61
28.83 +/- 2.22
13.92 +/- 1.83
20.23 +/- 3.10

Male BM
42.12 +/- 2.45
37.93 +/- 3.45
3.29 +/- 0.38
4.21 +/- 0.28

Female LN
30.51 +/- 2.777
32.18 +/- 3.08
59.99 +/- 5.88
50.94 +/- 1.82

Male LN
16.72 +/- 7.17
10.46 +/- 2.62
28.68 +/- 7.43
34.93 +/- 4.85

One experiment used female C57BL/6 mice and the other used male (n=3). CD19 (% live single
lymphocytes) was detected using extracellular staining and flow cytometry.
Table 4.2

B220 expression in splenocytes (SPLC), bone marrow (BM), and lymph nodes
(LN) in two independent experiments.

%B220
Female SPLC
SAL/CO
35.30 +/- 11.86
SAL/TCDD 43.90 +/- 14.49
EAE/CO
26.75 +/- 2.92
EAE/TCDD 39.57 +/- 3.83

Male SPLC
10.46 +/- 1.73
60.06 +/- 3,71
18.91 +/- 4.14
22.04 +/- 1.31

Female BM
26.56 +/- 2.34
26.37 +/- 3.46
10.40 +/- 3.09
16.66 +/- 3.00

Male BM
36.44 +/- 3.55
34.93 +/- 2.62
3.02 +/- 0.28
3.47 +/- 0.41

Female LN
30.40 +/- 2.72
31.56 +/- 3.06
58.97 +/- 5.92
50.13 +/- 2.07

Male LN
11.23 +/- 3.87
7.04 +/- 1.39
16.99 +/- 4.87
22.90 +/- 3.19

One experiment used female C57BL/6 mice and the other used male (n=3). B220 (% live single
lymphocytes) was detected using extracellular staining and flow cytometry.
Table 4.3

CD5 expression in splenocytes (SPLC), bone marrow (BM), and lymph nodes
(LN) in two independent experiments.

%CD5
Female SPLC
SAL/CO
18.94 +/- 10.53
SAL/TCDD 14.22 +/- 9.05
EAE/CO
21.87 +/- 2.51
EAE/TCDD 13.84 +/- 2.56

Male SPLC
13.22 +/- 2.86
28.05 +/- 0.33
11.52 +/- 11.43
12.89 +/- 0.20

Female BM
4.41 +/- 0.56
5.27 +/- 0.84
5.69 +/- 0.95
5.13 +/- 1.21

Male BM
7.96 +/- 1.11
3.90 +/- 0.42
1.08 +/- 0.24
0.79 +/- 0.16

Female LN
64.79 +/- 2.90
60.08 +/- 2.65
35.26 +/- 5.18
43. 16 +/- 1.47

Male LN
32.23 +/- 16.65
14.55 +/- 3.71
36.11 +/- 13.51
44.53 +/- 9.26

One experiment used female C57BL/6 mice and the other used male (n=3). CD5 (% live single
lymphocytes) was detected using extracellular staining and flow cytometry.
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Expression of B220 and CD19 is positively correlated.

CD19 and B220 were detected in splenocytes, lymphocytes, and bone marrow using flow
cytometry. Data from all four experimental groups from two independent experiments, one with
female and the other with male C57BL/6 mice, was pooled (n=24). R square values: 0.6873 (A),
0.9902 (B), and 0.7713 (C).
TCDD Effect on IgG Production in B cells in Various Tissues
Preliminary results showed that TCDD most affected IgG production in CD19populations of B cells (Figure 4.3). Therefore, these studies focused on IgG production in CD19, B220-, and CD5- populations in the spleen, lymph nodes, and bone marrow.

Figure 4.3

Intracellular IgG increased was most notably increased in CD19- B cells.

This upregulation was sensitive to inhibition by TCDD. This effect is demonstrated in Q3-1.
Cells were stained with viability dye followed by Fc receptor blockade. Extracellular IgG was
blocked using an unstained IgG antibody prior to permeabilization. Cells were stained with
extracellular CD19-PeCy7 and intracellular IgG-APC. Cells are gated on live lymphocytes.
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TCDD modestly reduced IgG expression in CD19-, B220-, and CD5- B cells in the
splenocytes of females but increased or did not affect expression in the splenocytes of males.
TCDD modestly suppressed IgG expression in CD19- and B220- populations in the lymph nodes
of female mice. In males, TCDD did not affect IgG expression in CD19-, B220-, or CD5populations in the lymph nodes. In both female and male mice, TCDD did not have much of an
effect on IgG expression in any of the measured B cell subsets in the bone marrow (Figure 4.4).
TCDD Effect on CD24+CD38+ Expression in B cells in Various Tissues
TCDD did not significantly affect CD24 and CD38 expression in CD19+ or B220+
populations in the spleens, lymph nodes, bone marrow, or spinal cords of female mice. In males,
where CD24 and CD38 expression was overall lower than in females, TCDD significantly
suppressed CD24 and CD38 expression in CD19+, B220+, and CD5+ populations in the spleens
of mice without disease and in the lymph nodes of mice with disease. Interestingly, TCDD
slightly increased the CD5+CD24+CD38+ population in the spinal cords of both male and
female mice (Figure 4.5).
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Mice were euthanized on Day 18 and intracellular IgG was detected in splenocytes, lymph
nodes, and bone marrow using flow cytometry (n=3). Female mice were used in experiments 1
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(A, B, C) and 2 (D, E, F). Male mice were evaluated in experiment 3 (G, H, I). a p <0.05
difference between SAL/TCDD and SAL/CO. b p< 0.05 difference between EAE/CO and
SAL/CO. c p<0.05 difference between EAE/TCDD and EAE/CO.
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Expression of CD24 and CD38 in CD19, B220, and CD5 positive populations
varies

Mice were euthanized on Day 18, and extracellular CD24 and CD38 was detected in splenocytes,
lymph nodes, bone marrow, and spinal cord using flow cytometry (n=3). Female mice were used
in experiments 1 (A, B, C) and 2 (D, E, F). Male mice were evaluated in experiment 3 (G, H, I).
a p <0.05 difference between SAL/TCDD and SAL/CO. b p< 0.05 difference between EAE/CO
and SAL/CO. c p<0.05 difference between EAE/TCDD and EAE/CO.
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CHAPTER V
DISCUSSION
Development of MS has been linked to multiple causes, from viral infections to exposure
to environmental contaminants. In studies evaluating EAE after AhR ligand exposure, the results
have varied. Both TCDD and FICZ, another AhR ligand, have been shown to attenuate disease in
some instances and exacerbate disease in others, depending on the dosing paradigm (Yang et al.,
2016). These studies focused on B cell responses following subchronic, low dose TCDD
treatment in EAE without pertussis toxin (PTX). EAE disease was induced, although it was quite
modest, especially in experiment 1. This could be due to the fact that we don’t use the additional
immune adjuvant, pertussis toxin, in our EAE model. The absence of PTX, which is often used
to exacerbate EAE, more closely mimics a milder form of MS that exists at disease onset in
humans but does lead to lower clinical scores overall in EAE mice (Hofstetter et al., 2002).
However, TCDD still attenuated disease, but whether or not B cell marker expression or IgG
production aided attenuation remains the question.
When evaluating the results of this study, it is important to note the typical time course of
the development of the immune response against EAE. When EAE is initiated via active
immunization, the MOG emulsified in CFA triggers an inflammatory immune response against
the central nervous symptom. In about the first five days after disease induction, local dendritic
cells bind the MOG/CFA antigen and then infiltrate the lymph nodes. In the lymph nodes,
dendritic cells present the antigen to T cells and B cells, which then become activated. From
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about day 5 to day 10, these activated T cells and B cells circulate throughout the body, and
many move to the spleen, where differentiation takes place. Around day 10 to day 18, the T cells
and B cells have begun to move to the CNS where they release inflammatory cytokines and
recruit macrophages that result in demyelination and CNS injury (Kuerten and Lehmann, 2011).
Overall, CD19, B220, and CD5 expression in the spleen, bone marrow, and lymph nodes
of both male and female mice varied. However, there were some consistent patterns that should be
noted. For example, in both male and female mice, the presence of disease correlated to a decrease
in CD19 and B220 expression in the bone marrow and spleen but in increase in CD19 and B220
expression in the lymph nodes. In mice with disease, TCDD modestly increased CD19 and B220
expression in the spleen and bone marrow and did not consistently affect expression of the markers
in the lymph nodes. Interestingly, treatment with TCDD countered EAE’s effect by increasing
expression, although it did not increase CD19/B220 expression back to the levels demonstrated in
the control mice. Nevertheless, since CD19 plays a role in early B cell differentiation in the bone
marrow and late maturation in the spleen (Wang et al., 2012), the increase of CD19/B220
expression may signify that the presence of TCDD leads to a downregulation of B cell
differentiation in the spleen and bone marrow. Again, it is important to note that the data analyzed
here comes from a single time point, day 18. Therefore, it is possible that CD19 and B220
expression was more significantly affected by TCDD, but the effect may have occurred earlier in
the immune response.
As noted in the patterns above, expression of CD19 and B220 was correlated, especially in
the bone marrow and lymph nodes. This co-expression supports the idea that both CD19 and B220
are pan-B cell markers in mice (Wang et al., 2012 , Rodig et al., 2005) Since CD5 expression was
not strongly correlated with CD19 and B220 expression, the cells expressing CD19 and B220 are
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most likely B2 B cells (Sindhava and Bondada, 2012). B2 B cells make up the largest
subpopulation of B cells and differentiate into a variety of B cells, depending on chemokines, BCR
signaling, and presence of antigen. Because they can use the BCR to engulf an antigen, process it,
and present it to T cells, B2 cells play a role in T-dependent immune responses (Cano and Lopera,
2013), such as EAE (Fletcher et al., 2010). Although it seems clear as to why B2 cells may be
needed to mount an immune response in EAE, it is not as clear as to why both CD19 and B220 are
expressed and why their expression is correlated, regardless of the presence of disease or TCDD
treatment. It is known that CD19 is involved in B cell signaling by modulating the B cell receptor
(BCR)-dependent and BCR-independent signaling pathways, as well as MHC Class II-mediated
signaling. CD19 also plays an important role in B cell activation (Wang et al., 2012). B220 also
plays a role in the positive regulation of antigen receptor signaling, but its function is more critical
for T cell signaling and development than B cell signaling (Coughlin et al., 2015). Therefore, it is
possible that CD19 and B220 are expressed together because the former plays a more significant
role in the B cell signaling while the latter is needed for T cell signaling.
The third marker that was evaluated was CD5. Expression of CD5 did not correlate with
expression of CD19 and B220 and did not show consistent patterns of expression in the presence
of disease with or without treatment. Although the CD5 in our studies was variable, one EAE study
demonstrated that disease onset was delayed and disease severity was attenuated in mice lacking
CD5. Researchers found that T cells in CD5- mice had a higher rate of apoptosis and suggested
that CD5 helps to regulate T cell survival in EAE (Axtell et al., 2004). Therefore, CD5 may be
playing a bigger role in the progression of EAE than we initially thought.
As a whole, the expression of the three different B cell markers, CD19, B220, and CD5,
was variable in all three tissues. It is important to note that these data reflect expression of B cell
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markers at end-stage disease, day 18. Based on the timeline of disease progression described
above, it is known that the CNS is the main target organ at end-stage disease. On the other hand,
it is not likely that the lymph nodes and bone marrow are a target organ at end-stage disease, and
we are not still sure about the spleen. It is possible that TCDD does affect the B cell populations
spleen, bone marrow, and lymph nodes, but it may happen at an earlier stage in the immune
response, so future studies could evaluate expression at an earlier day. However, the focus of these
studies was end-stage disease, and the inconsistent data points to the need to evaluate more than
just expression of the markers in order to fully understand how B cell populations in EAE mice
are affected by TCDD. A more in depth look at the function of these markers could provide this
information. It is known that T cells from mice that were actively induced with EAE can be
transferred to healthy mice and initiate disease, a process known as passive induction (Stromnes
and Goverman, 2006). In order to study the function of B cells, B cells from the spleens of diseased
mice, both untreated and treated with TCDD, could be injected into new mice. These mice would
then be evaluated for physical changes to see if disease is induced as well as changes to expression
of cytokines and lymphocytes. Thus, we could gain greater insight into the actual function of B
cells in EAE and TCDD’s effect on that function.
In addition to evaluating expression of CD19, B220, and CD5, the production of IgG was
evaluated in populations lacking these markers. In the last few decades, there has been increasing
evidence of the role of immunoglobins in the pathogenesis of MS. It is thought that
immunoglobulins may bind to cells expressing MOG, causing tissue destruction (Wootla et al.,
2011). More notably, IgG in particular is able to fix and activate the classical complement
cascade, which leads to cell death. Therefore, IgG directed against MOG can activate the
complement cascade and destroy the cells making up the myelin sheath, leading to demyelination
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(Magliozzi et al., 2006). Another study demonstrated a direct correlation between antibodyproducing B cells and demyelination in the spinal cord. In sections of the spinal cord containing
many B cells, there was also significant demyelination whereas sections without B cell
infiltration maintained the myelin sheath. This study also found that IgG expression in the spinal
cord increased upon EAE induction but was mainly produced in B cells lacking CD19 (Kummari
et al., 2019). Our preliminary study also demonstrated that that IgG expression was increased in
CD19- populations upon EAE disease induction and then decreased upon treatment with TCDD
(Kummari et al.). This pattern suggests that B cells that have differentiated and lost CD19, and
most likely B220, expression are more susceptible to changes in IgG expression. Therefore, the
studies presented here focused on IgG expression in B cell populations lacking either CD19,
B220, or CD5 and since we already know that TCDD affects IgG expression in the spinal cord,
we evaluated IgG expression in the B cell populations of the spleen, bone marrow, and lymph
nodes.
We found that the effect of TCDD on IgG was most prominent in the spleen. In females,
TCDD modestly suppressed IgG expression in CD19-, B220-, and CD5- B cell populations in
the spleen. In males, TCDD significantly increased IgG expression in CD19- and B220- splenic
B cells and modestly increased IgG in CD5- splenic B cells in saline mice but had little effect on
IgG expression in EAE mice. These differences between female and male mice are not clear and
point to the need for repeated IgG studies, especially in male mice since they presented the most
inconsistent data. However, the data as a whole does show that IgG expression in the spleen was
more affected by TCDD than in the bone marrow and lymph nodes, suggesting that the spleen
may play a more important role as a target organ in end-stage disease.
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Although TCDD had modest effects on B cell marker expression and IgG expression, its
effect on a regulatory B cell population, identified by the co-expression CD24 and CD38, was
inconsistent in almost all B cell populations and tissues in male and female mice. However,
TCDD did increase the CD5+CD24+CD38+ population in the spinal cords of both male and
female mice with EAE. This observation is not consistent with the other study that supported the
idea that CD5 exacerbates disease (Axtell et al., 2004), but it does show that CD5 is an important
marker in the progression of EAE and should be more thoroughly evaluated in future studies
involving EAE. Additionally, the variable and inconsistent data regarding CD24 and CD38
expression in each of the populations may have also been affected by the fact that the data came
from day 18 of disease. This regulatory population could still be playing an important role in
disease development or in the TCDD mechanism of attenuation, but the effects may be occurring
at an earlier timepoint.
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CHAPTER VI
CONCLUSION
In summary, most of the data regarding the expression of different B cell markers in the
different tissues was variable. However, we did find that CD19 and B220 expression was
decreased in the spleen and bone marrow in EAE mice but then increased upon treatment with
TCDD, suggesting a possible mechanism of disease attenuation. Another interesting finding was
that CD19 and B220 expression was correlated in all experimental groups in all three tissues.
Although we are not sure why both markers are upregulated or suppressed at the same time, one
hypothesis is that both are needed, or not needed, in certain B cells because CD19 plays a more
significant role in B cell signaling while B220 plays a more significant role in T cell signaling.
Because previous studies demonstrated that IgG was most affected in CD19- B cell
populations in the spinal cord, we decided to evaluate the effect of TCDD on IgG expression in
CD19-, B220-, and CD5- populations in the spleen, lymph node, and bone marrow. Our results
showed that IgG expression was most affected in the spleen and also may be a possible sex
difference because TCDD decreased IgG expression in the B cell populations of females but
increased it in the B cells of males.
In order to study TCDD’s effect on a regulatory B cell subset, we analyzed the expression
of CD24 and CD38, which together can represent a regulatory cell. For this evaluation, we
evaluated CD19+CD24+CD38+, B220+CD24+CD38+, and CD5+CD24+CD38+ in the spleen,
bone marrow, lymph nodes, and spinal cord since this regulatory population has not been well
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characterized in any of these tissues. We found that TCDD had no significant or consistent
effects on the expression of CD24 and CD38 in almost all of the experimental groups in any of
the tissues, except that TCDD modestly increased the CD5+CD24+CD38+ population in the
spinal cords of both male and female mice with EAE, which could be important since the spinal
cord is known to be the primary target organ for end stage disease.
It is important to again point out that in these studies we looked at cells harvested 18 days
following disease initiation, which is considered end-stage disease in our model of EAE.
Although there were not many significant effects in the B cells of the bone marrow and lymph
nodes, the data we gathered still provides important information because it confirms that the
CNS, and possibly the spleen, are still the most likely target organs at end-stage disease. Before
these studies, we did not know what was happening in the bone marrow and lymph nodes, but
based on the results, we believe that if TCDD is affecting B cells in these tissues, it is most likely
exerting its effects earlier in the disease progression. Future studies could evaluate this
possibility.
Overall, the results of this study provide novel information about the effect of TCDD in B
cells in EAE, especially in the bone marrow and lymph nodes, at end-stage disease. Future
studies are needed to verify the results, particularly in males, which we looked at for the first
time, and to further access the changes in the function of the B cells, since expression of different
markers alone is not telling us enough. In light of these findings, we hope to contribute to the
understanding of TCDD’s mechanism of toxicity and immunosuppression and to further our
knowledge of AhR ligands as a potential treatment for autoimmune diseases.
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